Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes

Next Previous
X
Search
Trial Profile

An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs A 400-Sichuan Kelun-Biotech Biopharmaceutical (Primary)
  • Indications Brain metastases; Medullary thyroid cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Registrational; Therapeutic Use

    • Most Recent Events

    • 25 Jun 2024 Status changed from recruiting to active, no longer recruiting.
    • 01 May 2024 According to an Ellipses Pharma Media Release, company announced that the U.S. Food and Drug Administration (FDA) has confirmed the company's next generation selective RET inhibitor (SRI), EP0031/A400, is clear to progress into Phase 2 clinical development.
    • 01 May 2024 According to an Ellipses Pharma Media Release, the latest clinical data from the Ellipses Phase 1 study will be presented at ASCO in Chicago on June 3rd 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top